Can doubling the dose stop prostate cancer from worsening?
NCT ID NCT03458247
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is safe and effective for those with low drug levels in their blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abiraterone acetate
What this could lead to
If successful, this could show that a higher dose of abiraterone helps control prostate cancer longer in patients who start to progress on the standard dose.
What could go wrong
This is a small, early-phase study without a comparison group, so results may not be definitive. Higher doses may also increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, Cochin Hospital
Paris, Paris, 75014, France